Finch Therapeutics Group, Inc. FNCHQ
- Market cap
- $1.6M
- P/E
- 0.0×
Follow FNCHQ
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 263.10 | 9.00 | 2.96 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 675.00 | 328.50 | 18.30 |
High Price
|
|||
| — | — | — | — | — | — | — | 189 | 18 | 1 |
Employees
|
|||
| — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | 10 | 8 | 19 | 1 | 0 |
Revenue
|
|||
| — | — | — | — | — | 92.16% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | — | — | (21) | (39) | (58) | (115) | (78) |
EBT
|
|||
| — | — | — | — | — | (204.39%) | (509.66%) | (313.84%) | (13,315.45%) | (73,098.13%) |
EBT Margin
|
|||
| — | — | — | 0 | — | (21) | (39) | (58) | (115) | (75) |
Net Income
|
|||
| — | — | — | — | — | 0 | 1 | 2 | 6 | 2 |
Depreciation
|
|||
| — | — | — | — | — | 6.31 | 28.46 | 14.20 | 0.54 | 0.07 |
Revenue/Sh
|
|||
| — | — | — | — | — | (12.90) | (145.05) | (44.44) | (72.07) | (46.59) |
Earnings/Sh
|
|||
| — | — | — | — | — | (10.76) | (115.52) | (51.43) | (47.08) | (19.63) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | 0.00 | (9.71) | (12.20) | (1.37) | 0.83 |
Capex/Sh
|
|||
| — | — | — | — | — | (10.76) | (125.23) | (63.62) | (48.45) | (18.80) |
Free CF/Sh
|
|||
| — | — | — | — | — | (37.00) | 506.40 | 154.91 | 60.20 | 14.26 |
Book Value/Sh
|
|||
| — | — | — | — | — | 2 | 0 | 1 | 2 | 2 |
Shares
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | 22.47 | 22.47 | 21.07 | 25.15 | 9.99 |
PS Ratio
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 1.93 | 0.23 | 0.27 |
PB Ratio
|
|||
| — | — | — | — | — | 9.79 | 9.79 | 14.13 | (40.34) | 15.97 |
EV/Sales
|
|||
| — | — | — | — | — | (2.22) | (2.22) | (3.15) | 0.45 | (0.32) |
EV/FCF
|
|||
| — | — | — | — | — | (17) | (31) | (67) | (75) | (32) |
Op' Cash Flow
|
|||
| — | — | — | — | — | (1) | (3) | (16) | (2) | 1 |
Capex
|
|||
| — | — | — | — | — | (17) | (34) | (83) | (77) | (30) |
FCF
|
|||
| — | — | — | — | — | 41 | 95 | 128 | 60 | 22 |
Working Cap'
|
|||
| — | — | — | — | — | 143 | 2 | 5 | 15 | — |
Total Debt
|
|||
| — | — | — | — | — | 101 | (98) | (129) | (56) | (25) |
Net Debt
|
|||
| — | — | — | — | — | (60) | 137 | 202 | 96 | 23 |
Sh' Equity
|
|||
| — | — | — | — | — | (38.34%) | (28.76%) | (29.77%) | (59.05%) | (68.48%) |
ROA
|
|||
| — | — | — | — | — | 0.00% | (62.50%) | (50.92%) | (183.71%) | 0.00% |
ROIC
|
|||
| — | — | — | — | — | 26.74% | 50.68% | (109.21%) | (76.96%) | (126.06%) |
ROE
|
|||
Finch Therapeutics Group, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ITRMF Iterum Therapeutics PLC | $1.6M | 0.0× | Compare |
| NEXI NexImmune, Inc. | $1.6M | 0.0× | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | 0.0× | Compare |
| SLXN Silexion Therapeutics Corp | $1.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ABPO Abpro Holdings Inc. | $1.4M | 0.2× | Compare |
| TRVN Trevena, Inc. | $1.8M | 0.0× | Compare |
| BBLG Bone Biologics Corp. | $1.4M | 0.0× | Compare |
| CRIS Curis, Inc. | $1.8M | 0.0× | Compare |
Finch Therapeutics Group, Inc. (FNCHQ) key facts
- Finch Therapeutics Group, Inc. (FNCHQ) is a Biotechnology company in the Healthcare sector.
- Finch Therapeutics Group, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $107,000.00, down 87.6% from fiscal 2022.
- As of September 24, 2026, FNCHQ traded at $10.35, a market capitalization of $1.6 million.
- Return on equity was −126.1% and debt-to-equity 0.00.
Finch Therapeutics Group, Inc. (FNCHQ) Latest News
11 Dec
Finch Therapeutics Group, Inc. (FNCH) is positioned as a promising investment due to its innovative approach in microbiome therapeutics, particularly its lead product candidate, which targets various gastrointestinal disorders. The company has shown potential for growth through strategic partnerships and advancements in clinical trials. Additionally, FNCH's focus on addressing unmet medical needs in the microbiome space could enhance its market presence and attract investor interest, making it a noteworthy consideration for those looking to invest in biotech. Significant advancements in product development and strategic partnerships are likely to impact FNCH's market position and investor sentiment.
21 Oct
Finch Therapeutics Group, Inc. announced delisting from Nasdaq and SEC deregistration due to failure to comply with Nasdaq's requirements. Delisting and deregistration will have a significant impact on the company's future trajectory and market performance.
22 Nov
Billionaire Seth Klarman's Baupost Group reveals biotech stock picks, including Finch Therapeutics Group, Inc. (FNCH). Significant impact likely on Finch Therapeutics Group, Inc. (FNCH) future and market performance due to Baupost Group's investment.
9 Jun
Finch Therapeutics Group, Inc. announces a one-for-30 reverse stock split of its common stock to meet Nasdaq listing requirements. The reverse stock split may have a moderately noticeable influence on the company's financial performance and market positioning.
10 May
Finch Therapeutics Group, Inc. reports Q1 2023 financial results, announces clinical trial agreement with Brigham and Women's Hospital, amends license agreement with UMN, and implements executive leadership transition. The article describes significant strategic moves, partnerships, and leadership changes that could have a major impact on Finch Therapeutics Group, Inc.'s future trajectory and market performance.